Contract Services Clinical Research
AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...
August 17, 2026 | News
Kyowa Kirin Taps Cognizant and Benchling to Build AI-Powered Drug Discovery Foundation in Japan
Cognizant announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Rese...
August 17, 2026 | News
ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II cli...
August 17, 2026 | News
ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...
August 14, 2026 | News
Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device
Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digit...
August 13, 2026 | News
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...
August 12, 2026 | News
HanchorBio Partners with Taiwan Cancer Moonshot Team to Advance Precision Immunotherapy
Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate bioma...
August 11, 2026 | News
RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...
August 10, 2026 | News
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...
August 07, 2026 | News
Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial
Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...
August 06, 2026 | News
Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma
Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...
August 05, 2026 | News
From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC
BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...
August 04, 2026 | Interaction
8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026
Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...
July 29, 2026 | Analysis
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...
July 29, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
